BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
435
Employees435
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
435
Employees435

BCRX Key Statistics

Market cap
2.13B
Market cap2.13B
Price-Earnings ratio
7.02
Price-Earnings ratio7.02
Dividend yield
—
Dividend yield—
Average volume
5.82M
Average volume5.82M
High today
$8.52
High today$8.52
Low today
$8.31
Low today$8.31
Open price
$8.41
Open price$8.41
Volume
3.47M
Volume3.47M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

With a market cap of 2.13B, BioCryst(BCRX) trades at $8.52. The stock has a price-to-earnings ratio of 7.02.

On 2026-03-08, BioCryst(BCRX) stock moved within a range of $8.31 to $8.52. With shares now at $8.52, the stock is trading +2.5% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 3.47M, compared to an average daily volume of 5.82M.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

BCRX News

Simply Wall St 4d
A Look At BioCryst Pharmaceuticals Valuation After Its Profitability And Revenue Turnaround

BioCryst Pharmaceuticals (BCRX) drew fresh attention after reporting fourth quarter 2025 revenue of US$406.56 million and net income of US$245.85 million, compa...

A Look At BioCryst Pharmaceuticals Valuation After Its Profitability And Revenue Turnaround
TipRanks 4d
BioCryst reports inducement grants under Nasdaq listing rule

BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock un...

Simply Wall St 6d
BioCryst Pharmaceuticals Is Up 15.4% After First Profitable Year And HAE Portfolio Expansion - Has The Bull Case Changed?

In late February 2026, BioCryst Pharmaceuticals reported fourth-quarter 2025 revenue of US$406.56 million and net income of US$245.85 million, capping its first...

BioCryst Pharmaceuticals Is Up 15.4% After First Profitable Year And HAE Portfolio Expansion - Has The Bull Case Changed?

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More BCRX News

TipRanks 6d
BioCryst price target raised to $22 from $21 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on BioCryst (BCRX) to $22 from $21 and keeps an Outperform rating on the shares. While the company pr...

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.
Plug Power
NIO
Tilray Brands
SNDL
Nokia
Pfizer

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.